1. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis.
- Author
-
Tjernberg, Ivar, Henningsson, Anna J, Eliasson, Ingvar, Forsberg, Pia, Ernerudh, Jan, Tjernberg, Ivar, Henningsson, Anna J, Eliasson, Ingvar, Forsberg, Pia, and Ernerudh, Jan
- Abstract
OBJECTIVES: The aim of this study was to evaluate the chemokine CXCL13 and C6 antibodies separately and in combination in paired serum/cerebrospinal fluid (CSF) samples in the laboratory diagnosis of Lyme neuroborreliosis (LNB). METHODS: A large retrospective material with paired serum/CSF samples from 261 patients with clinically suspected LNB was investigated. Patients were divided into three main diagnostic groups based on original results of CSF pleocytosis and intrathecal anti-borrelia antibodies (purified flagellum). Levels of CXCL13, albumin, total IgM and IgG in paired samples and C6 antibodies in CSF were compared across diagnostic groups. RESULTS: A sensitivity of 99% and a specificity of 96% were achieved for CSF-Serum CXCL13 ratio. CSF-C6 antibodies performed with a sensitivity of 99% and a specificity of 88.0%. A combination of CSF-Serum CXCL13 ratio and CSF-C6 antibodies, evaluated in parallel, revealed a sensitivity of 99% and specificity of 98%. CONCLUSIONS: This study confirms CSF-CXCL13 as a reliable marker of LNB and suggests improved diagnostic performance especially in children with possible LNB., Original Publication: Ivar Tjernberg, Anna J Henningsson, Ingvar Eliasson, Pia Forsberg and Jan Ernerudh, Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis., 2011, Journal of Infection, (62), 2, 149-158. http://dx.doi.org/10.1016/j.jinf.2010.11.005 Copyright: Elsevier Science B.V., Amsterdam http://www.elsevier.com
- Published
- 2011
- Full Text
- View/download PDF